Global Psoriatic Arthritis Market 2015-2019

乾癬性関節炎治療薬の世界市場2015-2019

◆タイトル:Global Psoriatic Arthritis Market 2015-2019
◆商品コード:IRTNTR7499
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年12月16日
◆ページ数:101
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、乾癬性関節炎治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、乾癬性関節炎治療薬の世界市場規模及び予測、種類別分析、剤形別分析、投与経路(ROA)別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.

In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.

Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers
The TNF inhibitors aid in suppressing the inflammatory response in the patient’s body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
• TNF inhibitors
• PDE4 inhibitors
• Interleukin blockers
• Others

The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
• Mild psoriatic arthritis
• Moderate psoriatic arthritis
• Severe psoriatic arthritis

This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.

Leading vendors in this market are -
• Abbvie
• Amgen
• Janssen Pharmaceuticals
• Celgene
• UCB

Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology
• Research methodology
• Economic indicators

PART 05: Introduction
• Key market highlights

PART 06: Disease overview
• Understanding the disease
• Types of psoriatic arthritis
• Symptoms
• Risk factors
• Diagnosis
• Disease management
• Quality of life
• Epidemiology

PART 07: Pipeline portfolio

PART 08: Novel mechanisms targeted by pipeline candidates
• Small molecules
• Biologics

PART 09: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 10: Market segmentation by MoA
• TNF-alpha inhibitors
• PDE4 inhibitors
• IL blockers
• Others

PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 12: Market segmentation by severity of disease

PART 13: Market segmentation by route of administration
• Oral
• Parenteral
• Topical

PART 14: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid

PART 15: Geographical segmentation
• Psoriatic arthritis market in Americas
• Psoriatic arthritis market in EMEA
• Psoriatic arthritis market in APAC

PART 16: Market drivers
• Increase in public awareness
• Unmet medical needs
• Growing patient population
• Change in lifestyle patterns

PART 17: Impact of drivers

PART 18: Market challenges
• Increasing costs of biologics
• Loss of patent exclusivity of branded therapies
• Use of CAM by patients
• Adverse effects of drugs

PART 19: Impact of drivers and challenges

PART 20: Market trends
• Emergence of biosimilars
• Popularity of off-label and traditional treatment options
• Patient assistance programs in the US
• Dominance of market by biologics

PART 21: Vendor landscape
• Competitive scenario
• Market share analysis 2014
• Other prominent vendors

PART 22: Key vendor analysis
• AbbVie
• Amgen
• Celgene
• Janssen Pharmaceuticals
• UCB

PART 23: Appendix
• List of abbreviations

PART 24: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of psoriatic arthritis
Exhibit 03: Signs and symptoms of psoriatic arthritis
Exhibit 04: Risk factors for psoriatic arthritis
Exhibit 05: Diagnostic test for psoriatic arthritis
Exhibit 06: Treatment options for psoriatic arthritis
Exhibit 07: Management of psoriatic arthritis
Exhibit 08: Pipeline molecules for psoriatic arthritis
Exhibit 09: Psoriatic arthritis clinical trial by phase
Exhibit 10: Psoriatic arthritis clinical trial by status
Exhibit 11: Novel targets of the pipeline candidates
Exhibit 12: Tofacitinib
Exhibit 13: Ixekizumab
Exhibit 14: Sekukinumab
Exhibit 15: Bimekizumab
Exhibit 16: Global psoriatic arthritis market 2014-2019 ($ millions)
Exhibit 17: Five forces analysis
Exhibit 18: Segmentation of global psoriatic arthritis market by MoA
Exhibit 19: Segmentation of global psoriatic arthritis market by MoA 2014
Exhibit 20: Segmentation of global psoriatic arthritis market by type of molecule
Exhibit 21: Segmentation of global psoriatic arthritis market by severity of disease
Exhibit 22: Segmentation of global psoriatic arthritis market by route of administration
Exhibit 23: Segmentation of global psoriatic arthritis market by dosage form
Exhibit 24: Global psoriatic arthritis market by geography 2014
Exhibit 25: Psoriatic arthritis market in Americas 2014-2019 ($ millions)
Exhibit 26: Psoriatic arthritis market in EMEA 2014-2019 ($ millions)
Exhibit 27: Psoriatic arthritis market in APAC 2014-2019 ($ millions)
Exhibit 28: Global psoriatic arthritis market by geography 2014-2019 ($ millions)
Exhibit 29: Drivers in global psoriatic arthritis market
Exhibit 30: Impact of drivers
Exhibit 31: Challenges in global psoriatic arthritis market
Exhibit 32: Average annual cost of HUMIRA, Enbrel, and Remicade 2014 ($)
Exhibit 33: Approvals and patent expiries of branded biologics
Exhibit 34: Impact of drivers and challenges
Exhibit 35: Trends in global psoriatic arthritis market
Exhibit 36: YoY sales comparison of top drugs 2010-2014 ($ millions)
Exhibit 37: YoY sales comparison of top drugs 2010-2014 (%)
Exhibit 38: YoY global sales of HUMIRA 2010-2014 ($ millions)
Exhibit 39: AbbVie: Key takeaways
Exhibit 40: YoY global sales of Remicade 2010-2014 ($ millions)
Exhibit 41: YoY global sales of Simponi 2012-2014 ($ millions)
Exhibit 42: Janssen Pharmaceuticals: Key takeaways
Exhibit 43: YoY sales of Enbrel in US and Canada 2010-2014 (($ millions)
Exhibit 44: YoY sales of Enbrel in US 2010-2014 ($ millions)
Exhibit 45: YoY sales of Enbrel in Canada 2010-2014 ($ millions)
Exhibit 46: YoY sales of Enbrel in Japan 2010-2014 ($ millions)
Exhibit 47: Comparison of YoY sales of Enbrel in US, Japan, and Canada 2010-2014 ($ millions)
Exhibit 48: Amgen: Key takeaways
Exhibit 49: UCB: Key takeaways
Exhibit 50: Celgene: Key takeaways
Exhibit 51: AbbVie: Product segmentation by revenue 2014
Exhibit 52: AbbVie: Geographical segmentation by revenue 2014
Exhibit 53: Amgen: Business segmentation by revenue 2014
Exhibit 54: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 55: Amgen: Geographical segmentation by revenue 2014
Exhibit 56: Celgene: Product segmentation by revenue 2014
Exhibit 57: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 58: Celgene: Geographical segmentation by revenue 2014
Exhibit 59: Janssen Pharmaceuticals: Key therapeutic areas
Exhibit 60: UCB: Product segmentation by revenue 2014
Exhibit 61: UCB: Product segmentation by revenue 2013 and 2014
Exhibit 62: UCB: Geographical segmentation by revenue 2014
Exhibit 63: Geographical segmentation by revenue 2013 and 2014



【掲載企業】

Hoffmann-La Roche, Eli-lilly, Sanofi, Otsuka Holdings, Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, Celgene.

【資料のキーワード】

乾癬性関節炎、乾癬性関節炎治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[乾癬性関節炎治療薬の世界市場2015-2019] (Global Psoriatic Arthritis Market 2015-2019 / IRTNTR7499)販売に関する免責事項
[乾癬性関節炎治療薬の世界市場2015-2019] (Global Psoriatic Arthritis Market 2015-2019 / IRTNTR7499)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆